Clinical Trial Detail


Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at :

NCT ID NCT03430895
Title Evaluating Immune Therapy, Durvalumab (MEDI4736) With Tremelimumab for Metastatic, Non-transitional Cell Carcinoma of the Urinary Tract
Recruitment Completed
Gender both
Phase Phase II
Variant Requirements No
Sponsors Memorial Sloan Kettering Cancer Center

bladder adenocarcinoma

urethra cancer

bladder squamous cell carcinoma

renal pelvis squamous cell carcinoma

bladder carcinoma

urethra squamous cell carcinoma

ureter small cell carcinoma

urachus cancer

ureter carcinoma

ureter adenocarcinoma

urethra adenocarcinoma

renal pelvis carcinoma

renal pelvis adenocarcinoma


Durvalumab + Tremelimumab

Age Groups: senior | adult
Covered Countries USA

No variant requirements are available.